Authors
A de de Gramont, A Figer, M Seymour, M Homerin, A Hmissi, J Cassidy, C Boni, H Cortes-Funes, A Cervantes, G Freyer, D Papamichael, N Le Bail, C Louvet, D Hendler, F De Braud, C Wilson, F Morvan, A Bonetti
Publication date
2000/8/16
Journal
Journal of Clinical Oncology
Volume
18
Issue
16
Pages
2938-2947
Publisher
American Society of Clinical Oncology
Description
PURPOSE: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen. This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point.
PATIENTS AND METHODS: Four hundred twenty previously untreated patients with measurable disease were randomized to receive a 2-hour infusion of LV (200 mg/m2/d) followed by a 5FU bolus (400 mg/m2/d) and 22-hour infusion (600 mg/m2/d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1.
RESULTS: Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median …
Total citations
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024921511832452693293402962902853082682562352292121571731621451481207451
Scholar articles